CCR5 Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients.
Phase of Trial: Phase III
Latest Information Update: 27 Mar 2013
At a glance
- Drugs Maraviroc (Primary) ; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate
- Indications HIV-1 infections
- Focus Adverse reactions; Biomarker; Pharmacogenomic
- Acronyms CADIRIS
- 10 Jun 2017 Biomarkers information updated
- 27 Mar 2013 Status changed from active, no longer recruiting to completed.
- 06 Mar 2013 Results presented at the 20th Conference on Retroviruses and Opportunistic Infections.